{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:12:43Z","timestamp":1789535563173,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA097397"],"award-info":[{"award-number":["CA097397"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA114236"],"award-info":[{"award-number":["CA114236"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13058-017-0874-x","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T08:00:47Z","timestamp":1500451247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of WECARE Study Collaborative Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Reiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Sisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Concannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Mellemkj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Haile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonine L.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"874_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/oxfordjournals.aje.a116565","volume":"136","author":"JL Bernstein","year":"1992","unstructured":"Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992;136:925\u201336.","journal-title":"Am J Epidemiol."},{"key":"874_CR2","first-page":"855","volume":"8","author":"Y Chen","year":"1999","unstructured":"Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855\u201361.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"874_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/bjc.1986.201","volume":"54","author":"HH Storm","year":"1986","unstructured":"Storm HH, Jensen OM. Risk of contralateral breast cancer in Denmark: 1943-80. Br J Cancer. 1986;54:483\u201392.","journal-title":"Br J Cancer."},{"key":"874_CR4","unstructured":"Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr., editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000 National Cancer Institute, NIH Publ No 05-5302. Bethesda; 2006. \n                    https:\/\/seer.cancer.gov\/archive\/publications\/mpmono\/MPMonograph_complete.pdf\n                    \n                  ."},{"key":"874_CR5","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","volume":"29","author":"HB Nichols","year":"2001","unstructured":"Nichols HB, Berrington de Gonzalez A, Lacey Jr JV, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2001;29:1564\u20139.","journal-title":"J Clin Oncol"},{"key":"874_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.bjc.6601042","volume":"89","author":"CI Li","year":"2003","unstructured":"Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer. 2003;89:513\u20138.","journal-title":"Br J Cancer."},{"key":"874_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/0008-5472.CAN-06-3854","volume":"67","author":"K Hemminki","year":"2007","unstructured":"Hemminki K, Ji J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 2007;67:868\u201370.","journal-title":"Cancer Res."},{"key":"874_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/oxfordjournals.aje.a114971","volume":"128","author":"PL Hom","year":"1988","unstructured":"Hom PL, Thompson WD. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol. 1988;128:309\u201323.","journal-title":"Am J Epidemiol."},{"key":"874_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/0021-9681(87)90114-7","volume":"40","author":"PL Hom","year":"1987","unstructured":"Hom PL, Thompson WD, Schwartz SM. Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J Chronic Dis. 1987;40:1003\u201311.","journal-title":"J Chronic Dis."},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/bjc.1978.92","volume":"37","author":"P Prior","year":"1978","unstructured":"Prior P, Waterhouse JA. Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiologic analysis. Br J Cancer. 1978;37:620\u201334.","journal-title":"Br J Cancer"},{"key":"874_CR11","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887\u201392.","journal-title":"J Clin Oncol."},{"key":"874_CR12","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328\u201335.","journal-title":"J Clin Oncol."},{"key":"874_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/1055-9965.EPI-06-1003","volume":"16","author":"JA Largent","year":"2007","unstructured":"Largent JA, Capanu M, Bernstein L, Langholz B, Mellemkaer L, Malone KE, et al. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol Biomarkers Prev. 2007;16:906\u201311.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"874_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-012-2187-1","volume":"135","author":"N Druesne-Pecollo","year":"2012","unstructured":"Druesne-Pecollo N, Touvier M, Barrandon E, Chan DS, Norat T, Zelek L, et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat. 2012;135:647\u201354.","journal-title":"Breast Cancer Res Treat."},{"key":"874_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/jnci\/djm267","volume":"100","author":"L Bertelsen","year":"2008","unstructured":"Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, et al. Effect of systematic adjuvant treatment on risk for contralateral breast cancer in the Women\u2019s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100:32\u201340.","journal-title":"J Natl Cancer Inst."},{"key":"874_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13058-016-0726-0","volume":"18","author":"R Langballe","year":"2016","unstructured":"Langballe R, Mellemkjaer L, Malone KE, Lynch CF, John EM, Knight JA, et al. Systemic therapy and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res. 2016;18:65.","journal-title":"Breast Cancer Res."},{"key":"874_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"78","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011;78:771\u201384.","journal-title":"Lancet"},{"issue":"21","key":"874_CR18","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255\u201369.","journal-title":"J Clin Oncol"},{"key":"874_CR19","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.1995.13.7.1578","volume":"13","author":"P Broet","year":"1995","unstructured":"Broet P, de la Rochefordiere A, Scholl SM, Fourquet A, Mosseri V, Durand JC, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578\u201383.","journal-title":"J Clin Oncol."},{"key":"874_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-006-9445-z","volume":"105","author":"J Ji","year":"2007","unstructured":"Ji J, Hemminki K. Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat. 2007;105:229\u201336.","journal-title":"Breast Cancer Res Treat."},{"key":"874_CR21","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56:1038\u201345.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"874_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djh097","volume":"96","author":"SM Swain","year":"2004","unstructured":"Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004;96:516\u201323.","journal-title":"J Natl Cancer Inst."},{"key":"874_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1053\/ejso.1999.0711","volume":"25","author":"J Kollias","year":"1999","unstructured":"Kollias J, Ellis IO, Elston CW, Blamey RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. 1999;25:584\u20139.","journal-title":"Eur J Surg Oncol."},{"key":"874_CR24","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ejca.2011.05.004","volume":"47","author":"V Vichapat","year":"2011","unstructured":"Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Luchtenborg M. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer. 2011;47:1919\u201327.","journal-title":"Eur J Cancer."},{"key":"874_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1055-9965.EPI-10-1016","volume":"20","author":"L Bessonova","year":"2011","unstructured":"Bessonova L, Taylor TH, Mehta RS, Zell JA, Anton-Culver H. Risk of second breast cancer associated with hormone-receptor and HER2-neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:389\u201396.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"874_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jnci\/djp181","volume":"101","author":"AW Kurian","year":"2009","unstructured":"Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009;101:1058\u201365.","journal-title":"J Natl Cancer Inst."},{"key":"874_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s13058-014-0452-4","volume":"16","author":"C Rusner","year":"2014","unstructured":"Rusner C, Wolf K, Banderner-Greulich U, Stegmaier C, Holleczek B, Schubert-Fritschle G, et al. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. Breast Cancer Res. 2014;16:452.","journal-title":"Breast Cancer Res."},{"key":"874_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10549-012-2183-5","volume":"135","author":"BS Saltzman","year":"2012","unstructured":"Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CL. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat. 2012;135:849\u201355.","journal-title":"Breast Cancer Res Treat."},{"key":"874_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046535","volume":"7","author":"ME Sandberg","year":"2012","unstructured":"Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, et al. Estrogen receptor status in relation to risk of contralateral breast cancer: a population-based cohort study. PLoS One. 2012;7, e46535.","journal-title":"PLoS One."},{"key":"874_CR30","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","volume":"10","author":"WD Foulkes","year":"2004","unstructured":"Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029\u201334.","journal-title":"Clin Cancer Res."},{"key":"874_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W","volume":"83","author":"N Loman","year":"1998","unstructured":"Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutation or unknown susceptibility genes. Cancer. 1998;83:310\u20139.","journal-title":"Cancer."},{"key":"874_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol."},{"key":"874_CR33","doi-asserted-by":"publisher","first-page":"R199","DOI":"10.1186\/bcr771","volume":"6","author":"JL Bernstein","year":"2004","unstructured":"Bernstein JL, Langholz B, Haile RW, Bernstein L, Thomas DC, Stovall M, et al. Study design: evaluation gene-environment interactions in the etiology of breast cancer: the WECARE study. Breast Cancer Res. 2004;6:R199\u2013214.","journal-title":"Breast Cancer Res."},{"key":"874_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.2007.55-a","volume":"299","author":"CB Begg","year":"2008","unstructured":"Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1\/2 carriers. JAMA. 2008;299:194\u2013201.","journal-title":"JAMA."},{"key":"874_CR35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/jnci\/93.9.662","volume":"93","author":"JS Abrams","year":"2001","unstructured":"Abrams JS. Tamoxifen: Five versus ten years\u2014is the end in sight? J Natl Cancer Inst. 2001;93:662\u20134.","journal-title":"J Natl Cancer Inst."},{"key":"874_CR36","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"The Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"The Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451\u201367.","journal-title":"Lancet"},{"key":"874_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3109\/0284186X.2013.850738","volume":"53","author":"B Ejlertsen","year":"2014","unstructured":"Ejlertsen B, Jensen M, Mouridsen H, Danish Breast Cancer Cooperative Group. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2014;53:174\u201385.","journal-title":"Acta Oncol"},{"key":"874_CR38","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr3462","volume":"15","author":"MM Hefti","year":"2013","unstructured":"Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, et al. Estrogen receptor negative\/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;15:R68.","journal-title":"Breast Cancer Res."},{"key":"874_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cncr.25587","volume":"117","author":"D Huo","year":"2011","unstructured":"Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 2011;117:907\u201315.","journal-title":"Cancer."},{"key":"874_CR40","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature."},{"key":"874_CR41","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"874_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-011-1702-0","volume":"131","author":"RM Tamimi","year":"2012","unstructured":"Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131:159\u201367.","journal-title":"Breast Cancer Res Treat."},{"key":"874_CR43","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1200\/JCO.2005.04.076","volume":"23","author":"G Arpino","year":"2005","unstructured":"Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005;23:4687\u201394.","journal-title":"J Clin Oncol."},{"key":"874_CR44","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149\u201356.","journal-title":"Breast Cancer Res."},{"key":"874_CR45","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1158\/1055-9965.EPI-09-0301","volume":"18","author":"H Ma","year":"2009","unstructured":"Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, et al. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009;18:2214\u201320.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"874_CR46","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.","journal-title":"J Natl Cancer Inst"},{"key":"874_CR47","unstructured":"The SEER Program Code Manual, Revised Edition June 1992. National Cancer Institute, 1992"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-017-0874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-017-0874-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-017-0874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T09:31:05Z","timestamp":1589535065000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-017-0874-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1186\/s13058-017-0874-x","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]},"assertion":[{"value":"6 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants gave written informed consent before enrollment, and the study protocols were approved by the institutional review boards at the University of Iowa (IRB-01), Fred Hutchinson Cancer Research Center, Cancer Prevention Institute of California, University of Southern California, Beckman Research Institute of the City of Hope, University of California at Irvine, Mount Sinai Hospital, Danish Cancer Society and Memorial Sloan Kettering Cancer Center, and by the Committee for the Protection of Human Subjects of the State of California and the ethical committee system in Denmark.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Patrick Concannon owns stock in Amgen; Lene Mellemkjaer has an immediate family member who owns stock in Novo Nordisk and stock in Lundbeck and has an immediate family member employed at Novo Nordisk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"83"}}